We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Blasts Fake COVID-19 Treatments in Warning Letters

FDA Blasts Fake COVID-19 Treatments in Warning Letters

November 25, 2020

The FDA has issued a flood of warning letters during the pandemic to crack down on marketers of sham COVID-19 treatments.

As of Nov. 17, the agency said it had identified more than 1,200 “fraudulent and unproven medical products related to COVID-19.”

Under Operation Quack Hack, which began in March, agency investigators have “reviewed thousands of websites, social media posts and online marketplace listings, resulting in over 132 warning letters to sellers,” the agency said.

In two of the most recent warning letters, the agency zeroed in on claims by Bridgeport, W.Va.-based Pro Breath MD, and Scottsdale, Ariz.-based Vibrant Health Care. The letters noted that the FDA “is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose or cure COVID-19 in people.”

Pro Breath, which also does business as Dentist Select and OraCare, was cited for promoting its OraCare Health Rinse and OraCare Operatory Pre-Rinsing Set as COVID-19 treatments. The company’s website claimed, for example, that in a study, OraCare Rinse was found “greater than 99.99 percent effective against human coronavirus with no toxic effects on tissue.”

Vibrant was cited for offering “an umbilical cord-derived cellular product in the United States to mitigate, prevent, treat, diagnose or cure COVID-19 in people,” which the FDA deems an unapproved new drug, as well as an unapproved biological product for which an approved biologics license application would be required.

The FDA states that Vibrant made claims on its website, YouTube channel and Facebook page that “stem cells are proving to be effective in treating critically ill coronavirus patients. Stem cell therapy can also help build up the immune system and fortify lungs against viruses.”

The FDA asked both companies to stop making such claims and gave them 48 hours to describe the steps taken to correct the violations.

Neither company responded to requests for comment.

Read the two warning letters here: www.fdanews.com/11-24-20-WarningLetters.pdf. — Martin Berman-Gorvine

COVID-19

Upcoming Events

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

  • Purple_Approved_Stamp.gif

    Seno Medical Gets Premarket Approval for Breast Cancer Diagnostic

  • Triple Vaccine, needles

    Moderna to Start New Trial Adding Third Shot of COVID-19 Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing